|
Post by iamaverb on Feb 23, 2017 15:07:42 GMT
Not seeing any news, just profit taking for short term holders? That is how I read it and perhaps the market was taking out the stop losses. I have learned to wait 24 hours before I react. Think the day after the Brexit decision was reached. The market crashed expecting the boom, then no boom, and the market rallied. Nature came out with an article on using CRISPR to manufacture advanced CAR-T cells for immunotherapy cancer treatment. There are just too many potential revenue streams and avenues for me to ignore an investment in CRISPR. I posted more on fb at CRISPR InvestorCRISPR Genome-Editing Tool Takes Cancer Immunotherapy to the Next Level
|
|
|
Post by iamaverb on Feb 28, 2017 14:48:41 GMT
Cambridge, February 27th, 2017 The European Patent Office (EPO) has announced it intends to grant its first CRISPR-Cpf1 patent to the Broad Institute, MIT, and Harvard University, based on a patent application filed in June 2015. I was pleasantly surprised and heartened to see EDIT turn green today for the first time in 5 days. 'bout time. Editas to receive Cpf1 patent in Europe. CRISPR INVESTOR
|
|
|
Post by RLC on Mar 3, 2017 18:23:30 GMT
Grabbed a few call option contracts today on the weakness here. Really not understanding the selling...
|
|
|
Post by iamaverb on Mar 4, 2017 22:38:12 GMT
There was a lot of SEC notices out of Editas yesterday. They will provide updates and add color on the 7th of March in a cc.
|
|
|
Post by iamaverb on Mar 9, 2017 15:12:47 GMT
A lot has happened recently with Editas. Conference Call, 10-k released, stock authorizations, payments for the patent rights for the CRISPR-Cpf1 and more. The stock has fallen leading up to the news but is currently up 8% Editas Update
|
|
|
Post by iamaverb on Mar 11, 2017 2:16:08 GMT
Good end of the day volume for Editas to finish out the week with 20% of the daily volume traded in the last 30 minutes. Volume of 654,579 was some 20 times higher than CRSP, and over four times higher than NTLA. Editas share price fell in the first half of the week but closed roughly 10% higher on Friday. The announced 800K shares being released for sale by Editas should, in my opinion, sell quickly to one or more institutions. This past week's actions may mean the volatility is moving behind us as the public in general becomes more aware of CRISPR gene editing.
|
|
|
Post by stargazer on Mar 11, 2017 2:41:45 GMT
IAV Thanks for bringing the attention to the crispr stocks on this board. Used last week's down days in edit to start a small position.
|
|
|
Post by selluwud on Mar 14, 2017 13:27:08 GMT
|
|
|
Post by iamaverb on Mar 14, 2017 14:11:18 GMT
This story, Bill Gates as an early investor and more posted at CRISPR INVESTOR
|
|
|
Post by selluwud on Mar 14, 2017 15:33:22 GMT
|
|
|
Post by iamaverb on Mar 15, 2017 0:44:21 GMT
I am expecting an 8-K to be filed soon detailing to some degree the structure of and the amount of future royalties Editas may have coming to them. I would also expect the backend to be loaded in our favor, something along the scope and size of a REGN if this treatment proves successful.
|
|
|
Post by iamaverb on Mar 15, 2017 13:34:59 GMT
I am expecting an 8-K to be filed soon detailing to some degree the structure of and the amount of future royalties Editas may have coming to them. I would also expect the backend to be loaded in our favor, something along the scope and size of a REGN if this treatment proves successful. The 8-K is out. Ultimately the eye program it could be worth 100's of millions or more. The highlights: In connection with entering into the Agreement, Allergan is required to pay the Company a one-time up-front payment of $90.0 million. In addition, within 45 days of the acceptance by the applicable regulatory authority of the Company’s submission of an investigational new drug application with respect to the LCA10 Program, Allergan is required to pay the Company a one-time payment in the low-eight digits Program. Allergan is entitled to acquire from the Company an exclusive world-wide right and license to the Company’s background intellectual property any gene editing therapy product that results from such Collaboration Development Program during the term of the Agreement in any category of human diseases and conditions other than the diagnosis, treatment or prevention of any cancer in humans through the use of engineered T-cells and subject to specified other limitations. Allergan will be responsible for the development, manufacturing and commercialization of any Licensed Products and the Company will remain primarily responsible for conducting the LCA10 Program through the acceptance for filing of the first investigational new drug application with respect to the LCA10 Program. The Company is entitled to receive clinical, regulatory, and launch milestone payments from Allergan up to a low-nine-digit amount in the aggregate and further commercial milestone payments up to a high-eight-digit amount in the aggregate with respect to each Collaboration Development. In the aggregate, the Company is eligible to receive clinical, regulatory, launch, and commercial milestone payments that could exceed $200 million for an indication in the first field per Collaboration Development Program, as well as the potential for additional regulatory milestones for indications in up to two additional fields. The Company is also entitled to receive royalties in the high-single digit percentages with respect to net sales of Licensed Products, subject to certain reductions under specified circumstances, and the Company will remain obligated to pay all license fees, milestone payments, and royalties due to its upstream licensors based on Allergan’s exercise of its license rights with respect to Licensed Products With respect to the LCA10 Program and up to one other Collaboration Development Program of the Company’s choosing, following the exercise by Allergan of its Option to such programs, the Company will have the right to elect to participate in a profit-sharing arrangement with Allergan in the United States, under which the Company and Allergan would share equally in net profits and losses on specific terms to be agreed between the Company and Allergan, in lieu of Allergan paying royalties on net sales of any applicable Licensed Products in the United States. ir.editasmedicine.com/phoenix.zhtml?c=254265&p=irol-sec
|
|
|
Post by iamaverb on Mar 15, 2017 18:34:46 GMT
I am not sure why EDIT is down with what seems like a fairly safe and potentially lucrative collaboration. I see nothing but positives here with short and long term rewards. Wall Street is but a fickle avenue to travel on. Somebody knows something and if I wasn't all in I would be buying on this dip.
|
|
|
Post by stargazer on Mar 15, 2017 20:47:01 GMT
|
|
|
Post by iamaverb on Mar 16, 2017 13:57:45 GMT
I mentioned two days ago on the CRISPR Investor page that I thought the $90 million dollar upfront payment from Allergan might take the pressure off of Editas from having to do a stock offering in the near term. Looks like I was wrong as they decided (as many companies do at times of good news) TO OFFER UP 4,600,000 SHARES in a public offering. I had a feeling this was why the stock dropped after yesterday's news. Companies do this at a time of either strength or weakness to raise funds, and certainly Editas is coming from a position of strength. There will short term pain, but I firmly believe the institutions will snap up these shares at a small discount within a day of being offered, which won't affect the daily price with their buys. This additional cash infusion will give us a long runway to fund ongoing research. I expect the share price to be in the $28 to $32 dollar range by the end of the month. The use of proceeds and the assume offering price: (Selling the shares at this price will represent real strength as many companies raise money at a discount to the market). "We estimate that the net proceeds to us from this offering will be approximately $97.7 million, or approximately $112.4 million if the underwriters exercise in full their option to purchase additional shares of our common stock, in each case based on an assumed public offering price of $26.04 per share, which was the last reported sale price of our common stock on The NASDAQ Global Select Market on March 14, 2017, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We currently intend to use the net proceeds to us from this offering to fund preclinical studies and clinical trials for our LCA10 program and our other programs to treat genetic and infectious diseases of the eye, preclinical studies of our programs to treat non-malignant hematologic diseases, preclinical studies in our collaboration with Juno Therapeutics, preclinical studies of other research programs, continued expansion of our platform technology, and for working capital and other general corporate purposes."
|
|
|
Post by iamaverb on Mar 16, 2017 18:15:09 GMT
I mentioned two days ago on the CRISPR Investor page that I thought the $90 million dollar upfront payment from Allergan might take the pressure off of Editas from having to do a stock offering in the near term. Looks like I was wrong as they decided (as many companies do at times of good news) TO OFFER UP 4,600,000 SHARES in a public offering. I had a feeling this was why the stock dropped after yesterday's news. Companies do this at a time of either strength or weakness to raise funds, and certainly Editas is coming from a position of strength. There will short term pain, but I firmly believe the institutions will snap up these shares at a small discount within a day of being offered, which won't affect the daily price with their buys. This additional cash infusion will give us a long runway to fund ongoing research. I expect the share price to be in the $28 to $32 dollar range by the end of the month. The use of proceeds and the assume offering price: (Selling the shares at this price will represent real strength as many companies raise money at a discount to the market). "We estimate that the net proceeds to us from this offering will be approximately $97.7 million, or approximately $112.4 million if the underwriters exercise in full their option to purchase additional shares of our common stock, in each case based on an assumed public offering price of $26.04 per share, which was the last reported sale price of our common stock on The NASDAQ Global Select Market on March 14, 2017, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We currently intend to use the net proceeds to us from this offering to fund preclinical studies and clinical trials for our LCA10 program and our other programs to treat genetic and infectious diseases of the eye, preclinical studies of our programs to treat non-malignant hematologic diseases, preclinical studies in our collaboration with Juno Therapeutics, preclinical studies of other research programs, continued expansion of our platform technology, and for working capital and other general corporate purposes." Looks like the pain might be indeed short lived as the offering appears to be priced $26.04, which is 6% higher than the days close, and is trading close to that price a day later. I expect these shares to be snapped up within the day, and with no additional dilution overhang in front of the company, I believe we will be in the $28 to $32 range at the end of the month.
|
|
|
Post by iamaverb on Mar 17, 2017 12:51:24 GMT
Editas discounted the shares to investors by roughly 10% of the share price at market close today. It will be interesting to see how fast the shares are bought up. I also posted a recap of recent analyst ratings. Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $22.50 per share. The gross proceeds to Editas Medicine from this offering are expected to be approximately $90 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on March 22, 2017, subject to customary closing conditions. Morgan Stanley and J.P. Morgan are acting as joint book running managers for the offering. Cowen and Company is acting as lead manager, and JMP Securities is acting as co-manager. postanalyst.com/2017/03/16/the-way-analysts-see-editas-medicine-inc-edit/
|
|
|
Post by iamaverb on Mar 17, 2017 18:14:16 GMT
Based on today's volume of 5+ million shares by early afternoon, I think the JP Morgan and Cowan clients bought all 4.6 million shares and have probably flipped most of those for a quick profit. I called Fidelity for availability and was told they were probably sold from within those two groups. It is good to be connected. I am more bullish than ever on Editas.
|
|
|
Post by stargazer on Mar 17, 2017 18:43:14 GMT
Picked up my 2nd tranche of edit today
|
|
|
Post by iamaverb on Mar 17, 2017 20:21:42 GMT
Picked up my 2nd tranche of edit today I have to believe that was a good move as I bought some more myself. Let's see what happens Monday. From the Editas 8-K filed this afternoon. The shares are gone and were split up between 3 JP Morgan investment groups (3.3 million) and Cowan (.7 million). "The offering price of the Underwritten Shares to the public is $22.50 per share, and the Underwriters HAVE AGREED TO PURCHASE the Underwritten Shares from the Company pursuant to the Underwriting Agreement at a price of $21.15 per share (the “Purchase Price”). After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the offering of approximately $84.4 million."
|
|